Covering IPOs, Healthcare and Technology Stocks

Andrei Zakharov

Equity Capital Markets

Bicara Therapeutics / Equity Capital Markets

<ul>
<li>Bicara Therapeutics, a clinical-stage biotech company with focus on the treatment of patients with HPV-negative head and neck cancer, files for a $200M IPO.</li>
<li>The biotech firm was backed by Biocon Limited, India’s largest biopharmaceutical company, venture capital and investment firms, among others.  </li>
<li>I believe Bicara Therapeutics will succeed in its pivotal Phase 2/3 trial of their bifunctional antibody in combination with Keytruda (pembrolizumab) during 2025.</li>
</ul>


Bicara Therapeutics, a clinical-stage biotech company with focus on the treatment of patients with HPV-negative head and neck cancer, files for a $200M IPO.
The biotech firm was backed by Biocon Limited, India’s largest biopharmaceutical company, venture capital and investment firms, among others.  
I believe Bicara Therapeutics will succeed in its pivotal Phase 2/3 trial of their bifunctional antibody in combination with Keytruda (pembrolizumab) during 2025.


Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC

United States

Bicara Therapeutics Inc. operates as a biotech company. The Company focuses on treating cancer head-on by combining the precision of targeted therapies with the power of tumor microenvironment modulators to create better medicines for patients. Bicara Therapeutics serves Worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bicara Therapeutics (BCAX US)

Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC

Bicara Therapeutics, backed by Biocon Limited, files for a $200M IPO in the United States. Their bifunctional antibody in combination with...

Andrei Zakharov

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Bicara Therapeutics IPO: A Promising Combination with Merck’s Keytruda For Patients With HNSCC

​Bicara Therapeutics, backed by Biocon Limited, files for a $200M IPO in the United States. Their bifunctional antibody in combination with...

Andrei Zakharov

Bicara Therapeutics, backed by Biocon Limited, files for a $200M IPO in the United States. Their bifunctional antibody in combination with...